Repligen Corporation (RGEN)
NASDAQ: RGEN · Real-Time Price · USD
115.44
-0.47 (-0.41%)
May 12, 2026, 9:33 AM EDT - Market open
Repligen Employees
Repligen had 2,000 employees as of December 31, 2025. The number of employees increased by 222 or 12.49% compared to the previous year.
Employees
2,000
Change (1Y)
222
Growth (1Y)
12.49%
Revenue / Employee
$381,670
Profits / Employee
$25,699
Market Cap
6.51B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,000 | 222 | 12.49% |
| Dec 31, 2024 | 1,778 | -5 | -0.28% |
| Dec 31, 2023 | 1,783 | -242 | -11.95% |
| Dec 31, 2022 | 2,025 | 173 | 9.34% |
| Dec 31, 2021 | 1,852 | 724 | 64.18% |
| Dec 31, 2020 | 1,128 | 367 | 48.23% |
| Dec 31, 2019 | 761 | 213 | 38.87% |
| Dec 31, 2018 | 548 | 72 | 15.13% |
| Dec 31, 2017 | 476 | 240 | 101.69% |
| Dec 31, 2016 | 236 | 68 | 40.48% |
| Dec 31, 2015 | 168 | 32 | 23.53% |
| Dec 31, 2014 | 136 | 20 | 17.24% |
| Dec 31, 2013 | 116 | -4 | -3.33% |
| Dec 31, 2012 | 120 | -17 | -12.41% |
| Dec 31, 2011 | 137 | 69 | 101.47% |
| May 6, 2010 | 68 | -1 | -1.45% |
| May 31, 2009 | 69 | 13 | 23.21% |
| May 27, 2008 | 56 | 11 | 24.44% |
| Jun 30, 2007 | 45 | 2 | 4.65% |
| Jun 6, 2006 | 43 | 6 | 16.22% |
| Jun 7, 2005 | 37 | -3 | -7.50% |
| Jun 7, 2004 | 40 | -4 | -9.09% |
| May 15, 2003 | 44 | 5 | 12.82% |
| May 15, 2002 | 39 | -1 | -2.50% |
| May 15, 2001 | 40 | 13 | 48.15% |
| May 15, 2000 | 27 | 3 | 12.50% |
| May 15, 1999 | 24 | 0 | - |
| May 29, 1998 | 24 | 4 | 20.00% |
| May 15, 1997 | 20 | 5 | 33.33% |
| Jun 14, 1996 | 15 | -89 | -85.58% |
| Mar 31, 1995 | 104 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Baxter International | 37,500 |
| Solventum | 20,584 |
| Align Technology | 20,290 |
| Teleflex | 15,500 |
| The Cooper Companies | 15,000 |
| AptarGroup | 14,000 |
| Avantor | 13,500 |
| Bausch + Lomb | 13,000 |
RGEN News
- 5 days ago - Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference - GlobeNewsWire
- 5 days ago - Repligen price target raised to $160 from $145 at Barclays - TheFly
- 5 days ago - Repligen price target lowered to $165 from $180 at JPMorgan - TheFly
- 6 days ago - Repligen price target lowered to $142 from $152 at Jefferies - TheFly
- 7 days ago - Repligen Earnings Call Transcript: Q1 2026 - Transcripts
- 7 days ago - Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97 - TheFly
- 7 days ago - Repligen reports Q1 adjusted EPS 48c, consensus 38c - TheFly
- 7 days ago - Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance - GlobeNewsWire